Defunct Company
Total Trials
25
As Lead Sponsor
14
As Collaborator
11
Total Enrollment
1,854
NCT03811145
An Investigation of Tendoncel, a Novel Topical Platelet Lysate Gel, in the Treatment of Lateral Epicondylitis
Phase: Phase 2
Role: Lead Sponsor
Start: May 31, 2014
Completion: Nov 30, 2015
NCT02975687
CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
Phase: Phase 1
Role: Collaborator
Start: Nov 30, 2016
Completion: Dec 31, 2018
NCT03029338
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Start: Jun 8, 2017
Completion: Jun 22, 2021
NCT04011293
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
Phase: Early Phase 1
Start: Jul 31, 2019
Completion: Apr 30, 2022
NCT04034446
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
Start: Sep 30, 2019
Completion: Dec 1, 2020
NCT04232826
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
Start: Jan 15, 2020
Completion: Nov 1, 2022
NCT03515291
A Trial of Cardiac Injections of iMP Cells During CABG Surgery
Start: Jan 31, 2020
Completion: Jul 31, 2021
NCT04230473
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Start: Mar 13, 2020
NCT04586478
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Start: Oct 26, 2020
Completion: Sep 30, 2025
NCT04684147
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Start: Dec 24, 2020
Completion: Dec 31, 2026
NCT04690192
CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma
Phase: Phase 1/2
Start: Jan 1, 2021
Completion: Dec 30, 2024
NCT06316791
Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
Start: Dec 14, 2021
Completion: Dec 13, 2025
NCT05667506
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Start: Feb 7, 2023
Completion: May 30, 2027
NCT05552053
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
Phase: Phase 2/3
Start: Jun 1, 2023
Completion: Jun 1, 2026
NCT06231368
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Start: Feb 4, 2024
Completion: Aug 31, 2025
NCT06461351
Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection
Phase: N/A
Start: Mar 30, 2024
Completion: Mar 30, 2040
NCT06450067
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
Start: Jun 5, 2024
Completion: Jun 5, 2029
NCT06608342
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Start: Jun 25, 2024
Completion: May 30, 2028
NCT06608732
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Start: Aug 1, 2024
Completion: Jul 1, 2028
NCT06676982
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
Start: Jan 7, 2025
Completion: Aug 31, 2026
NCT06826430
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
Start: Mar 1, 2025
Completion: Dec 31, 2027
NCT06009107
A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
Start: Jun 30, 2025
Completion: Dec 30, 2027
NCT06005649
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Start: Sep 30, 2025
Completion: Jun 30, 2027
NCT07091370
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
Start: Dec 27, 2025
Completion: Mar 30, 2028